HDAC inhibitors and therapeutic methods using the same

Patent metadata

Field	Value
Publication number	US-11739064-B2
Application number	US-202017099360-A
Country	US
Kind code	B2
Filing date	Nov 16, 2020
Priority date	Sep 3, 2015
Publication date	Aug 29, 2023
Grant date	Aug 29, 2023

Abstract

Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed.

First claim

What is claimed:

1. A method of inhibiting HDAC, comprising administering to an individual in need thereof a therapeutically effective amount of a compound of formula:
(Ia):

wherein A is selected from the group consisting of
—C(═O)NHheteroaryl, —NHC(═O)heteroaryl, aryl, heteroaryl, and

 wherein B and C are, independently, aryl or heterocyclyl and n is 2 or 3;
or a pharmaceutically acceptable salt thereof; or
(Ib):

wherein A is selected from the group consisting
of, —NHC(═O)alkyl, —NHC(═O)cycloalkyl, —NHC(═O)heteroaryl, aryl, and heteroaryl; n is 0 or 1;
and p is 0 or 1; or a pharmaceutically acceptable salt thereof.

2. A method of inhibiting HDAC comprising administering to an individual in need thereof a therapeutically effective amount of a compound selected from the group consisting of

or a pharmaceutically acceptable salt thereof; wherein Boc is tert-butoxycarbonyl; and Bz is benzoyl.

3. The method of claim 1 , wherein the HDAC is HDAC6.

4. The method of claim 1 , further comprising administering a therapeutically effective amount of a second therapeutic agent.

5. The method of claim 1 , wherein the individual in need thereof is a cancer patient.

6. The method of claim 4 wherein the second therapeutic agent is selected from anticancer agents, antiemetic agents, hematopoietic colony stimulating factor, opioid analgesics agents, and anxiolytic agents.

7. The method of claim 1 , wherein the individual in need thereof suffers from a disease or condition selected from a neurological disease, a neurodegenerative disorder, peripheral neuropathy, a traumatic brain injury, stroke, a parasitic infection, autism, or an autism spectrum disorder.

8. The method of claim 7 , wherein the disease or condition is a neurological disease, a neurodegenerative disorder, peripheral neuropathy, or a traumatic brain injury selected from Huntington's disease, Parkinson's disease, Alzheimer's disease, ischemic stroke, multiple sclerosis, amyotrophic lateral sclerosis (ALS), spinal bulbar muscular atrophy (SBMA), spinal muscular atrophy, lupus, or schizophrenia.

9. The method of claim 7 , wherein the disease or condition is a parasitic infection selected from the group consisting of malaria, toxoplasmosis, trypanosomiasis, helminthiasis, and a protozoal infection.

10. The method of claim 9 , further comprising coadministering to the individual an antimalarial compound selected from the group consisting of an aryl amino alcohol, a cinchona alkaloid, a 4-aminoquinoline, a type 1 or type 2 folate synthesis inhibitor, an 8-aminoquinoline, an antimicrobial, a peroxide, a naphthoquinone, and an iron-chelating agent.

11. The method of claim 10 , wherein the antimalarial compound is selected from the group consisting of quinine, quinidine, mefloquine, halofantrine, chloroquine, amodiaquine, proguanil, chloroproguanil, pyrimethamine, primaquine, 8-[(4-amino-l-methylbutyl)aminb]-2,6-dimethoxy-4-methyl-5-[(3-trifluoromethyl)phenoxy]quinoline succinate (WR238,605), tetracycline, doxycycline, clindamycin, azithromycin, fluoroquinolones, artemether, arteether, artesunate, artelinic acid, atovaquone, and desferrioxamine.

12. The method of claim 11 , wherein the antimalarial compound is chloroquine.

13. A method of increasing sensitivity of a cancer cell to cytotoxic effects of a radiotherapy and/or a chemotherapy comprising contacting the cell with a compound of formula:
(Ia):

wherein A is selected from the group consisting of
—C(═O)NHheteroaryl, —NHC(═O)heteroaryl, aryl, heteroaryl, and

 wherein B and C are, independently, aryl or heterocyclyl and n is 0-4;
or a pharmaceutically acceptable salt thereof; or
(Ib):

wherein A is selected from the group consisting
of, —NHC(═O)alkyl, —NHC(═O)cycloalkyl, —NHC(═O)heteroaryl, aryl, and heteroaryl; n is 0 or 1; and p is 0 or 1; or a pharmaceutically acceptable salt thereof, in an amount sufficient to increase the sensitivity of the cell to the radiotherapy and/or the chemotherapy.

14. The method of claim 13 , wherein the cell is an in vivo cell.

15. The method of claim 1 , wherein individual in need thereof is suffering from a disease or conditions selected from Hashimoto's thyroiditis, pernicious anemia, Addison's disease, psoriasis, diabetes, rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, Sjogren's syndrome, dermatomyositis, lupus erythematosus, multiple sclerosis, myasthenia gravis, Reiter's syndrome, arthritis, rheumatic disease, hemolytic anemia, aplastic anemia, pure red cell anemia, idiopathic thrombocytopaenia, systemic lupus erythematosus, polychondritis, sclerodoma, Wegener granulomatosis, dermatomyositis, chronic active hepatitis, Steven-Johnson syndrome, idiopathic sprue, inflammatory bowel disease, endocrine ophthalmopathy, Graves disease, sarcoidosis, primary biliary cirrhosis, juvenile diabetes, uveitis, keratoconjunctivitis sicca, and glomerulonephritis.

16. A method of treating pancreatic cancer, comprising administering to an individual in need thereof a therapeutically effective amount of a compound of formula:
(Ia):

wherein A is selected from the group consisting of
—C(═O)NHheteroaryl, —NHC(═O)heteroaryl, aryl, heteroaryl, and

 wherein B and C are, independently, aryl or heterocyclyl and n is 2 or 3;
or a pharmaceutically acceptable; or
(Ib):

wherein A is selected from the group consisting
of, —NHC(═O)alkyl, —NHC(═O)cycloalkyl, —NHC(═O)heteroaryl, aryl, and heteroaryl; n is 0 or 1; and p is 0 or 1; or a pharmaceutically acceptable salt thereof.

Assignees

• Univ Illinois

Inventors

• Kozikowski Alan
• Gaisina Irina

Classifications

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• C07D261/10 Primary

  with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms · CPC title

• A61K31/4155

  non condensed and containing further heterocyclic rings · CPC title

• A61K31/42

  Oxazoles · CPC title

• A61K31/422

  not condensed and containing further heterocyclic rings · CPC title